Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-29
2008-01-29
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S275000, C544S122000, C544S295000, C544S323000
Reexamination Certificate
active
10495885
ABSTRACT:
Compounds of formula (1) are described in which Raand Rbis each independently a hydrogen atom or a group Rc, or Raand Rbtogether form an oxo (═O) or thio (═S) group; X is a N atom or an optionally substituted CH group: Y is a —O— or —S— atom or —SO— or —SO2— group or an optionally substituted —CH2— or —NH— group with the proviso that when Raand Rbtogether form an oxo (═O) or thio (═S) group Y is an optionally substituted —CH2— or —NH-group; L1is a covalent bond or a linker atom or group; p is zero or the integer 1; Alk1is an optionally substituted C1-10aliphatic or C1-10heteroaliphatic chain; n is zero the integer 1, 2 or 3 with the proviso that when n is zero Y is an optionally substituted —CH2— group; Ar is an optionally substituted C6-12aromatic or C1-9heteroaromatic group; m is zero or the integer 1, 2 or 3; q is zero or the integer 1 or 2; R1, Rcand Rdare hydrogen atoms or the substituents described in the patent specification; and the salts, solvates, hydrates and N-oxides thereof. The compounds are potent and selective inhibitors of p38 kinase and are useful in the treatment of immune or inflammatory disorders.
REFERENCES:
patent: 6162927 (2000-12-01), Winn et al.
patent: WO 99/58523 (1999-11-01), None
patent: WO 00/59510 (2000-10-01), None
patent: WO 01/64676 (2001-09-01), None
Ulrich, Crystallization—4. Crystal Characteristics, Kirk-Othmer Encyclopedia of Chemical Technology, Aug. 2002.
Vippagunta et al., Crystalline Solids, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
West, Solid Solutions, Solid State Chemistry and its applications, pp. 358 & 365, 1988.
Adams, J.L., et al., “p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines,” Progress in Medicinal Chemistry,Elsevier Science, King, F.D., et al. (Eds.), 2001, 38, 1-60.
Allen, M., et al., “Deficiency of the stress kinase p38α results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells,”J. Exp. Med., 2000, 191, 859-869.
Badger, A.M., et al., “Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function,”J. Pharm.&Exp. Ther., 1996, 279, 1453-1461.
Basha, A., et al., “Structure-activity relationships of pyrimido-pyrimidine series of 5-lipoxygenase inhibitors,”Med. Chem. Res., 1996,6, 61-67.
Cohen, P., “The search for physiological substrates of MAP and SAP kinases in mammalian cells,”Trends Cell Biol., 1997, 7, 353-361.
Dinarello, C.A., “An update on human interleukin-1 : from molecular biology to clinical relevance,”J. of Clinical Immunology, 1985, 5(5), 287-297.
Doza, Y.N., et al., “Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells,”FEBS Lett., 1995, 364, 223-228.
Driver, M.S., et al., “A second-generation catalyst for aryl halide amination: mixed secondary amines from aryl halides and primary amines catalyzed by (DPPF)PdC12,”J. Am. Chem. Soc., 1996, 118, 7217-7218.
Enslen, H., et al., “Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6,”J. of Biol. Chem., 1998, 273(3), 1741-1748.
Griswold, D.E., et al., “Pharmacology of cytokine suppressive anti-inflammatory drug binding protein (CSBP), a novel stress-induced kinase,”Pharmacol. Comm., 1996, 7, 323-329.
Grunberg, K., et al., “Effect of rhinovirus 16 (RV16) cold on airway responsiveness to indirect stimuli in asthmatics,”Am. J. Crit. Care Med., 1997, 155, p. A743 (abstract).
Hale, K.K., et al., “Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages,”Am. J. of Immun., 1999, 162, 4246-4252.
Hunter, T., “Protein kinase classification,”Methods in Enzymology, Academic Press, 1991, 200, 3-37.
Kotlyarov, A., et al., “MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis,”Nature Cell Biol., 1999, 1, 94-97.
Lee, J.C., et al., “Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors,”Annals N.Y. Acad. Sci., 1993, 696, 149-170.
Lee, J.C., et al., “Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002,”Int. J. Immunopharm., 1988, 10(7), 835-843.
Lee, J.C., et al., “A protein kinase involved in the regulation of inflammatory cytokine biosynthesis,”Nature, 1994, 372, 739-746.
Louie, J., et al., “Palladium-catalyzed amination of aryl triflates and importance of triflate addition rate,”J. Org. Chem., 1997, 62, 1268-1273.
McDonnell, P.C., et al., “Localization of the human stress responsive MAP kinase-like CSAIDs binding protein (CSBP) gene to chromosome 6p21.3/21.2,”Genomics, 1995, 28, 301-302.
Subauste, M.C., et al., “Infection of a human respiratory epithelial cell line with rhinovirus, Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure,”J. Clin. Invest., 1995, 96, 549-557.
Takekawa, M., et al., “A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK,”Cell, 1998, 95, 521-530.
Turner, R.B., et al., “Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds,”Clin. Infec. Dis., 1998, 26, 840-846.
Wolfe, J.P., et al. “An improved catalyst system for aromatic carbon—nitrogen bond formation: the possible involvement of bis(phosphine) palladium complexes as key intermediates,”J. Am. Chem. Soc., 1996, 118, 7215-7216.
Wolfe, J.P., et al., “Nickel-catalyzed amination of aryl chlorides,”J. Am. Chem. Soc., 1997, 119, 6054-6058.
Wolfe, J.P., et al., “Room temperature catalytic amination of aryl iodides,”J. Org. Chem., 1997, 62, 6066-6068.
Wolfe, J.P., et al., “Improved functional group complatibility in the palladium-catalyzed amination of aryl bromides,”Tetrah. Lett., 1997, 38(36), 6359-6362.
Zhu, Z., et al., “Rhinovirus stimulation of interleukin-6 in vivo and in vitro, evicence for nuclear factor kB-dependent transcriptional activation,”J. of Clin. Invest., 1996, 97(2), 421-430.
Brookings Daniel Christopher
Cubbon Rachel Jane
Davis Jeremy Martin
Franklin Richard Jeremy
Langham Barry John
Celltech R&D Limited
McDonnell Boehnen & Hulbert & Berghoff LLP
Rao Deepak
LandOfFree
Pyridine and pyrimidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridine and pyrimidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridine and pyrimidine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3955618